Cargando…

Glucose transporter-1 inhibition overcomes imatinib resistance in gastrointestinal stromal tumor cells

Imatinib mesylate (imatinib) is the primary agent of choice used to treat gastrointestinal stromal tumors (GIST). However, drug resistance to imatinib poses a major obstacle to treatment efficacy. In addition, the relationship between imatinib resistance and glycolysis is poorly understood. Glucose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shima, Takafumi, Taniguchi, Kohei, Tokumaru, Yoshihisa, Inomata, Yosuke, Arima, Jun, Lee, Sang-Woong, Takabe, Kazuaki, Yoshida, Kazuhiro, Uchiyama, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600406/ https://www.ncbi.nlm.nih.gov/pubmed/34738628 http://dx.doi.org/10.3892/or.2021.8218

Ejemplares similares

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Delta‐like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy
por: Matsuo, Kentaro, et al.
Publicado: (2019)

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
por: Masucci, Maria Teresa, et al.
Publicado: (2023)

Chloroquine Combined with Imatinib Overcomes Imatinib Resistance in Gastrointestinal Stromal Tumors by Inhibiting Autophagy via the MAPK/ERK Pathway
por: Zheng, Song, et al.
Publicado: (2020)

Should we target “intermediate expression” of HER2 in older estrogen receptor positive patients?
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Uptake of MicroRNAs from Exosome-Like Nanovesicles of Edible Plant Juice by Rat Enterocytes
por: Ito, Yuko, et al.
Publicado: (2021)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
por: Katsumata, Ryo, et al.
Publicado: (2023)

Keloid Nodule Metabolic Activity for Continuous Expansion
por: Ueda, Koichi, et al.
Publicado: (2022)

Delta‐like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview
por: Matsuo, Kentaro, et al.
Publicado: (2021)

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours
por: Liu, Juan, et al.
Publicado: (2022)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Update on imatinib for gastrointestinal stromal tumors: duration of treatment
por: Linch, Mark, et al.
Publicado: (2013)

Organoids Are Limited in Modeling the Colon Adenoma–Carcinoma Sequence
por: Tokumaru, Yoshihisa, et al.
Publicado: (2021)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors
por: Liu, Feiyang, et al.
Publicado: (2019)

Imatinib in gastrointestinal stromal tumour: Northern Cancer Network experience
por: Azribi, F, et al.
Publicado: (2009)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors
por: Sicklick, Jason K., et al.
Publicado: (2013)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors
por: Takahashi, Tsuyoshi, et al.
Publicado: (2017)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Gastrointestinal Stromal Tumor With Chondrosarcomatous Dedifferentiation Following Imatinib Therapy
por: Koufopoulos, Nektarios, et al.
Publicado: (2021)

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021)

Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors
por: Cao, Lei, et al.
Publicado: (2022)

A narrative review of imatinib-resistant gastrointestinal stromal tumors
por: Hayashi, Yujiro, et al.
Publicado: (2021)

Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis
por: Niikura, Ryota, et al.
Publicado: (2016)

Clinical silence of pulmonary lymphoepithelioma-like carcinoma with subcutaneous metastasis: a case report
por: Shima, Takafumi, et al.
Publicado: (2019)

The Role of the Microbiome on the Pathogenesis and Treatment of Colorectal Cancer
por: Yu, Irene, et al.
Publicado: (2022)

A large esophageal gastrointestinal stromal tumor that was successfully resected after neoadjuvant imatinib treatment: case report
por: Yanagawa, Senichiro, et al.
Publicado: (2014)

Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020)

Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer
por: Tokumaru, Yoshihisa, et al.
Publicado: (2021)

Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective
por: Date, Ravindra S, et al.
Publicado: (2008)

Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy
por: Annaberdyev, Shohrat, et al.
Publicado: (2009)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oie16lrgbijo0bom9ejem013vv